close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Echinacea – No Help Against Common Cold?

Studies of Echinacea’s cold-fighting properties show mixed results, with a recent large study1 suggesting no benefit at all. Echinacea did not prevent colds, and it did not ease cold symptoms.

Echinacea is a popular herbal remedy for treating the common cold; however, clinical trials have produced conflicting reports about its effectiveness. Consistent testing of Echinacea is complicated by the fact that a variety of influences, including variable growing conditions of the Echinacea plant, contribute to varying chemical composition between Echinacea preparations.

Native North Americans used the roots of the Echinacea plant (Echinacea angustifolia), also known as “purple coneflower”, to treat a variety of infections and wounds, from snakebites to skin problems such as acne and boils. Echinacea became commercially popular in the late 1800s as a cold remedy, and entered the alternative-therapy commercial mainstream in North America in the 1960s.

The recent study by Turner et al., published in the July 28 issue of the New England Journal of Medicine (NEJM) tested the effectiveness of three different preparations, each with a different plant-chemical composition, of Echinacea against rhinovirus (the virus associated with the common cold).

Study Protocol and Results

A total of 437 volunteers randomly received either preventative treatment with Echinacea (that is, treatment starting seven days before exposure to rhinovirus – also called “virus challenge”) – or treatment with Echinacea (that is, treatment at the time of virus challenge) or placebo. Researchers identified two main efficacy targets: cold prevention and relief of cold symptoms.

Results were taken from 399 volunteers challenged with rhinovirus type 39, who were observed in a closed setting for five days.

No statistically significant differences in infection-rate or symptom severity were seen among volunteers taking any of the Echinacea extracts. Similarly, among treated volunteers, no differences were noted in mucous production volume or in inflammatory markers, such as polymorphonuclear leukocyte or interleukin-8 concentrations in nasal-lavage specimens.

Study results therefore indicate that Echinacea extracts do not offer clinically significant health benefits against the common cold.

In an accompanying editorial2 in the NEJM, Dr. Wallace Sampson of Stanford University argues that the study’s findings should warn against using Echinacea as an effective cold remedy. Dr. Sampson is Editor of Scientific Review of Alternative Medicine.

Because this was a large, multi-centered, randomized, blinded trial, Dr. Sampson notes that, “…unless some obscure protocol violation occurred, the trial results are real."

Turner et al.’s clinical trial was supported by the National Institutes of Health’ National Center for Complementary and Alternative Medicine (NCCAM), which has three additional clinical trials of Echinacea underway, according to Dr. Sampson.

References:

  1. An Evaluation of Echinacea angustifolia in Experimental Rhinovirus Infections, Ronald B. Turner et al., New England Journal of Medicine, Volume 353(Number 4):341-348, July 28, 2005.
  2. Studying Herbal Remedies, Wallace Sampson, MD, New England Journal of Medicine, Volume 353:337-339(Number 4), July 28, 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...